Anna Bechtel, Lucas Kettner, Marie Jenz, Daniel Mopils, Lutz Fischer
{"title":"Recombinant production of a diamine oxidase in Komagataella phaffii and in vitro degradation of histamine in simulated intestinal fluid","authors":"Anna Bechtel, Lucas Kettner, Marie Jenz, Daniel Mopils, Lutz Fischer","doi":"10.1016/j.jbiotec.2025.05.003","DOIUrl":null,"url":null,"abstract":"<div><div>Diamine oxidase (DAO-1) from <em>Yarrowia lipolytica</em> was recombinantly produced in <em>Komagataella phaffii</em> in fed-batch bioreactor cultivations using the constitutive <em>GAP</em> and methanol-inducible <em>AOX1</em> promoters. Utilizing an exponential glucose feed, a maximum DAO-1 activity of 43 ± 7 µkat/L<sub>culture</sub> was achieved after 37 h of cultivation using the <em>GAP</em> promoter. When the <em>AOX1</em> promoter was used, a maximum DAO-1 activity of 230 ± 13 µkat/L<sub>culture</sub> was achieved after 90 h of cultivation with a stepwise increase in the methanol feed. Thus, approximately 15- (<em>GAP</em> promoter) and 82-fold (<em>AOX1</em> promoter) higher DAO-1 activities were obtained in <em>K. phaffii</em> compared to homologous recombinant production in <em>Y. lipolytica</em>. The DAO-1 produced in <em>K. phaffii</em> has been partially purified and was formulated as a sucrose-based tablet containing 4500 nkat DAO-1 activity. The DAO-1 tablet was tested for histamine degradation in a simulated intestinal fluid in the presence of food components, and approximately 90 % of the histamine applied initially (75 mg) was degraded in 90 minutes. This is the first time that a DAO-1 tablet has been able to break down such large amounts of histamine under simulated intestinal fluid conditions, which could help people with histamine intolerance in the future.</div></div>","PeriodicalId":15153,"journal":{"name":"Journal of biotechnology","volume":"405 ","pages":"Pages 39-47"},"PeriodicalIF":4.1000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of biotechnology","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168165625001130","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Diamine oxidase (DAO-1) from Yarrowia lipolytica was recombinantly produced in Komagataella phaffii in fed-batch bioreactor cultivations using the constitutive GAP and methanol-inducible AOX1 promoters. Utilizing an exponential glucose feed, a maximum DAO-1 activity of 43 ± 7 µkat/Lculture was achieved after 37 h of cultivation using the GAP promoter. When the AOX1 promoter was used, a maximum DAO-1 activity of 230 ± 13 µkat/Lculture was achieved after 90 h of cultivation with a stepwise increase in the methanol feed. Thus, approximately 15- (GAP promoter) and 82-fold (AOX1 promoter) higher DAO-1 activities were obtained in K. phaffii compared to homologous recombinant production in Y. lipolytica. The DAO-1 produced in K. phaffii has been partially purified and was formulated as a sucrose-based tablet containing 4500 nkat DAO-1 activity. The DAO-1 tablet was tested for histamine degradation in a simulated intestinal fluid in the presence of food components, and approximately 90 % of the histamine applied initially (75 mg) was degraded in 90 minutes. This is the first time that a DAO-1 tablet has been able to break down such large amounts of histamine under simulated intestinal fluid conditions, which could help people with histamine intolerance in the future.
期刊介绍:
The Journal of Biotechnology has an open access mirror journal, the Journal of Biotechnology: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review.
The Journal provides a medium for the rapid publication of both full-length articles and short communications on novel and innovative aspects of biotechnology. The Journal will accept papers ranging from genetic or molecular biological positions to those covering biochemical, chemical or bioprocess engineering aspects as well as computer application of new software concepts, provided that in each case the material is directly relevant to biotechnological systems. Papers presenting information of a multidisciplinary nature that would not be suitable for publication in a journal devoted to a single discipline, are particularly welcome.